GNA Biosolutions Selected as Finalist for AACC’s Inaugural Disruptive Technology Award.


The Disruptive Technology Award of the AACC (American Associationof Clinical Chemistry) will be awarded for the first time in Chicago in July 2018

GNA Biosolutions GmbH has created a breakthrough platform technology called Pulse Controlled Amplification (PCA) that is used to detect dangerous pathogens within minutes, with the sensitivity and specifi­city of laboratory-based molecular diagnostics. GNA is currently developing an ultrafast ­
(15 minutes or less), portable, and inexpensive integrated sample-to-result device for infectious disease testing at the Point of Care (POC) as well as molecular tests for some of the most pressing global health care problems today, including tuberculosis, MRSA and antibiotic-resistant Gram-negative bacteria. The company was recently selected as a finalist for the inaugural AACC (American Association of Clinical Chemistry) Disruptive Technology Award, which recognizes innovative testing solutions that improve patient care through diagnostic performance or access to high quality testing. As one of three finalists in this year’s competition, the GNA team will present data on their technology during a special session at the 70th AACC Annual Scientific Meeting, being held July 29 till August 2 in Chicago, Illinoiss.